A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET
about
Advances of Molecular Imaging in EpilepsyStrategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Role of (drug) transporters in imaging in health and disease.Central neurotoxicity in cancer chemotherapy: pharmacogenetic insights.Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat dataReversal of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar.Reproducibility of quantitative (R)-[11C]verapamil studies.Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.P-glycoprotein function at the blood-brain barrier: effects of age and gender.Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.P-glycoprotein Mediates Postoperative Peritoneal Adhesion Formation by Enhancing Phosphorylation of the Chloride Channel-3.Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects.Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor.Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoatePET and SPECT radiotracers to assess function and expression of ABC transporters in vivoA novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrierIctal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.Altered GABAA receptor density and unaltered blood-brain barrier [11C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis.P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil.Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier.Radiopharmaceuticals for assessing ABC transporters at the blood-brain barrier.Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[11C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy.Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11 C]verapamil in elderly vs. young subjects.Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study.Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain.A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil.Mapping the Binding Site of the Inhibitor Tariquidar That Stabilizes the First Transmembrane Domain of P-glycoprotein.
P2860
Q26750477-A45EFE2A-EFFD-4FEC-A66B-3AB8F1D88BC2Q30366921-51B00563-69C8-4569-A4BB-5BA329C7B476Q30854787-4FE049E8-97AB-4876-9576-4341EFFFCDCCQ33857581-B9E0E228-35EA-44A8-BA9B-6F3BA1599EE6Q34100185-1D38B253-C816-45A3-8B3B-E41AD70E6BD6Q34581006-50CFD5F5-6E2F-4B46-A258-9F9C1F6669AAQ35742284-94DADDBC-3D86-4E48-A59A-3E32738EB16BQ35831488-1821C6A3-E4AF-44D9-A6D3-5D092053DC18Q35996706-3579D228-07AF-4ADE-8EBA-014165D75A3FQ36049576-F1DE0E96-569C-47F7-AA0A-E38E05FD3FADQ36382013-29B1B30E-FE0B-494D-96E7-8E0E2DFE3BB9Q36462753-28A8E3A9-0DD6-4440-A7E2-B59267B1700BQ36510853-4C3A0AB6-9FDA-404E-B48F-899BC54C9704Q36525662-86654022-4FD2-4053-8329-420517AC237AQ36613936-10EBDDCE-9B35-4AF0-9418-0C7F2044F8CFQ36638627-DB063EED-16AA-45E8-9134-91D8A34AD6F3Q36947636-7B2C7307-2E69-44B1-A5EB-460169A4324BQ36947641-8B5A85AA-1993-46C8-BB76-4621A6B80159Q36949086-8D8BFA66-EA06-46E0-8545-B97F793229C6Q36949815-F985332A-0625-47DE-9FAD-49564463D97FQ36949864-1A581733-B195-413A-9172-0BD983B2E9FCQ36953090-71B7AC2D-F2A1-469C-A3A9-F196117C74F7Q36955931-09E875F6-BBD4-4D15-879A-387B9521DC3CQ37081979-D8DEDE24-70DF-45FD-86D8-E45780BDC396Q37177013-17FAEA53-EE38-4719-8C5D-E7D4247DDA67Q37185659-34C5728C-712C-44D3-890E-731223AC38B3Q37514707-8BC7B564-8D8C-4911-9DBA-9085EC309C7CQ38058376-BA572F81-6625-48C8-9E57-6115724E44C3Q38166961-5BCC1907-D377-4F03-91C8-43D256E84729Q38351240-9528B688-E8EC-4C98-BBB3-3B8FC1683EF4Q38420352-1732E378-799B-48CE-BB9F-02EEEA9CA9E8Q38841102-FA29E6B2-997C-4591-B84A-6EC3E73D0DC0Q38844653-C8138546-7B27-40FD-90C3-E45E4694FD93Q39341824-DFCFADF5-70E1-4DE8-BD18-31F270C115A0Q40308640-EBE86354-888E-465A-BDC8-0060A0C64994Q41775684-026B0ED9-0FE5-496C-9289-37EDB188C16FQ41823653-8860A6E5-8B55-4D1B-BD1B-1FAAF298C042Q42091226-4EFD3F2B-AF09-474F-9773-116EC3B4F85BQ42585832-7976F980-3163-468C-9D37-DEE5F0F7A736Q43099273-DF4636FA-A8BD-4164-B75E-0E9029FAD5AF
P2860
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
A pilot study to assess the ef ...... with (R)-11C-verapamil and PET
@en
type
label
A pilot study to assess the ef ...... with (R)-11C-verapamil and PET
@en
prefLabel
A pilot study to assess the ef ...... with (R)-11C-verapamil and PET
@en
P2093
P2860
P50
P1476
A pilot study to assess the ef ...... with (R)-11C-verapamil and PET
@en
P2093
Claudia C Wagner
Kurt Kletter
Markus Müller
Peter Chiba
Rudolf Karch
Stephan Kopp
Thomas Feurstein
Wolfgang Löscher
P2860
P304
P356
10.2967/JNUMED.109.063289
P407
P577
2009-11-12T00:00:00Z